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THE evaluation of treatment of disseminated sclerosis where long, natural
remissions occur is difficult. Allison (1950) found that in a series of 40 cases first
seen in 1929, 12 had survived when revisited in 1949. The longest duration of the
disease amongst the survivors was 39 years, and 5 had had the complaint for
over 30 years, the average being 27-28 years. These cases had had no arsenical
treatment. This emphasizes the extreme variability of the course of the disease,
and shows that the prognosis is often better than is usually realized. During a
recent investigation into the status of 91 patients who had been diagnosed for
TABLE
CASES T REATEI)
C C C
3~~~~~~ F 23 .. 48..I..0..5..0..
9~~~~~~ ,, 23 .. 12v.0..1 .0..0..
~~ ~ ~ ~ d-
20 ... F ... 20 ... 248 ... I ... 17 ... 5 ... 0 ... 1(
23 ... F ... 236 ... 128 ... I ... 12 ... 16 ... 0 ... 0
270 ... F ... 20 ... 24 ... 18 ... 17 ... 0 ... I ... 01
25 ... F ... 29 ... 32 ... 2 ... 2 ... 12 ... 2 0 ..
'
29 ... M ... 28 ... 74 ... 1 ... 1 .. 0 ... 14 ... 0
35 ... M ... 27 ... 60 ... 17 ... 22 ... 0 ... 5 ... o(
39 ... M ... 32 ... 24 ... 4 ... 10 ... 10 ... 0 ... 0
47 ... F ... 26 ... 28 ... 2 ... l ... 0 ... 18 ... 0
0 ~ ~ ~
'I OTALS I0 .. F7 .. 264 .. 490) .. 47 .. 83 .. 43 .. 40 .. 28
M3
3VERAGES ... 26.4 ... 489 ... 4.7 ... 8.3 ... 4.3 ... 4. ... 2.8
AVERAGE I2OTAL DURATION 19.4
N.A.B. column : Total number of injections.
Time Column : Interval to nearest yeai- between onset and beginnling Of tr-eatmenlt.
62at least ten years, the opportunity was taken to compare cases which had been
treated with intravenous arsenicals, Neoarsphenamine and Silver Salvarsan, with
a series of control cases (Millar, 1949).
Only those patients who had received more than three courses of eight
injections in the early stages of the disease were considered to have had the
minimum treatment likely to affect the course of such a disease process. Ten
cases only fulfilled these requirements. The ten control cases were chosen as those
with as nearly as possible in this series, a similar type and age of onset. These
ten control cases had received only a few injections.
The course of the disease in each patient was divided, to the nearest year, into
four stages
1.
2.
3.
Able to carry on gainful employment.
Able to do light work.
Unable to work, but able to walk a little and look after themselves with
assistance.
4. Bedridden.
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*Cases 27 and 36. The long interval between onset and beginning of treatment is.
explained by a long initial symptomless remission.
Controls: Chosen as those cases with little treatment and as similar a type and age
of onset as possible.
63This sub-division made comparison easier, but it must be remembered that
different occupations would influence the first two stages.
The two groups, treated and controls, are compared in the table. This method
of comparison, unfortunately, does not fulfil the requirements of a statistical
approach and would probably not be considered valid by a purist. However, I
plead my case on several points. Firstly, the long period of observation; and
secondly, the similarity of the treated and control groups clillically. Little more
can be expected from a clinical evaluation. The figures suggest that treatment
with arsenicals has little effect on the coturse of the disease. This confirms the
present-day opinion of most neurologists.
DIscusSION.
There is no known treatment of disseminated sclerosis which is generally
accepted to influence favourably the course of the disease. Fashions in treatment
come and go, and arsenicals have enjoyed a long regime and are still in favour in
some clinics. In such a long-standing condition, it is only possible to evaluate
treatment after many years. The literature contains only accounts of short-term
therapy, general impressions, statements of faith and accounts of the treatment of
one or two cases. The basis for the use of arsenicals in disseminated sclerosis was
founded on the erroneous idea that it was spirochaetal ir aetiology (Siemerling,
1918). Many authors have supported the use of intravenous arsenicals (Adams
et al., 1924; Kalberlah, 1919; O;snato, 1928; Perrin, 1920; Prados and Such,
1922; Sauer, 1926; Schafsen, 1924; Stern-Piper, 1920). Others have either found
inconclusive results or decided against the use of arsenicals. (Fleck, 1921;
Simmonds, 1920; Speer, 1920; Veraguth, 1924; Wichura, 1920).
However, no attempt, as far as the author is aware, has been made to analyse
the end-results after a number of years or compare them again.st a control series.
It was for this reason considered that present investigations were worth while
despite the fact that arsenical treatment is not accepted at present in this
department.
CONCLUSIONS.
An attempt has been made to compare the course of the disease in ten patients
suffering from disseminated sclerosis treated with intravenous arsenicals, with
that of ten similar controls. No significant difference in clinical status could be
seen about ten years later.
If the results of this investigation are generally true, it does not seem justifiable
to submit patients to the real risk of toxic complications and the possibility of
syringe jaundice.
I wish to thank the physicians of the Royal Victoria Hospital, Belfast, for
permission to use their cases, and Dr. R. S. Allison for his help and encouragement.
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REVIEW
ARCHIVES OF THE MIDDLESEX HOSPITAL. Edinburgh: E. & S. Living-
stone Ltd.
THE Archives of the Middlesex Hospital has reappeared after a lapse of twenty-five years. Not
many will remember the original Archives, but, judging from a brief introduction to the new
Archives by Victor Bonney, many notable papers were published, and many well-known names
in medicine to-day were among the early contributors.
The new journal has got off to a good start. The papers in the first number are all clinical
and reach a high standard. These papers are typical of the great clinical tradition of the London
teaching hospitals, and one believes that the new Archives will worthily maintain and strengthen
these traditions.
Dr. Douglas McAlpine, who edits the Archives, is to be congratulated, and Messrs. E. & S.
Livingstone, the publishers, have produced a beautiful journal, which it is a pleasure to read.
D. A. D. M.
65